Basically we (much like Triangle) are trying to avoid benign lumped into the crazy category. The market potential at 3% penetration is already ludicrous so going beyond this is just counterproductive.
The amazing thing is we could sell RC220 bisantrene priced as a generic (i.e the same as doxorubicin) and we would still be a multiple billion dollar company. I doubt there is another biotech company in the world that could claim that.
Ann: Race to Present at TechKnow July Conference, page-56
-
- There are more pages in this discussion • 77 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.54 |
Change
-0.065(4.05%) |
Mkt cap ! $262.4M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.62 | $1.51 | $261.3K | 168.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 15.59pm 09/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |